Characterization of a rarely reported STAT5B/RARA gene fusion in a young adult with newly diagnosed acute promyelocytic leukemia with resistance to ATRA therapy

Cancer Genet. 2019 Sep:237:51-54. doi: 10.1016/j.cancergen.2019.06.007. Epub 2019 Jun 12.

Abstract

The detection of PML/RARA or variant RARA rearrangements is critical for the diagnosis and treatment of patients with newly diagnosed acute promyelocytic leukemia (APL). While most cases of APL harboring the PML/RARA fusion respond to all-trans retinoic acid (ATRA), some variant RARA rearrangements are ATRA insensitive. Herein, we report a 27-year-old male with newly diagnosed, rapidly progressive APL and a rarely described STAT5B/RARA fusion with known resistance to ATRA therapy. While the PML/RARA dual-color dual-fusion fluorescence in situ hybridization (FISH) probe study was negative, the RARA break-apart probe study revealed an atypical RARA rearrangement in 95% of nuclei. A next generation sequencing assay, mate-pair sequencing, was subsequently performed to further characterize the RARA rearrangement and identified the RARA gene fusion partner STAT5B.

Keywords: Acute promyelocytic leukemia (APL); Mate-pair sequencing (MPseq); Next generation sequencing (NGS); RARA; STAT5B.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Gene Fusion*
  • Humans
  • In Situ Hybridization, Fluorescence
  • Leukemia, Promyelocytic, Acute / drug therapy
  • Leukemia, Promyelocytic, Acute / genetics*
  • Male
  • Retinoic Acid Receptor alpha / genetics*
  • STAT5 Transcription Factor / genetics*
  • Tretinoin / therapeutic use*

Substances

  • RARA protein, human
  • Retinoic Acid Receptor alpha
  • STAT5 Transcription Factor
  • STAT5B protein, human
  • Tretinoin